WO2006117171A1 - Method for preparing a ginkgo extract having a reduced content of 4'-o-methyl pyridoxine and/or biflavones - Google Patents
Method for preparing a ginkgo extract having a reduced content of 4'-o-methyl pyridoxine and/or biflavones Download PDFInfo
- Publication number
- WO2006117171A1 WO2006117171A1 PCT/EP2006/004039 EP2006004039W WO2006117171A1 WO 2006117171 A1 WO2006117171 A1 WO 2006117171A1 EP 2006004039 W EP2006004039 W EP 2006004039W WO 2006117171 A1 WO2006117171 A1 WO 2006117171A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- biflavones
- content
- original
- methyl pyridoxine
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 82
- SVINQHQHARVZFF-UHFFFAOYSA-N Ginkgotoxin Chemical compound COCC1=C(CO)C=NC(C)=C1O SVINQHQHARVZFF-UHFFFAOYSA-N 0.000 title claims abstract description 68
- 238000000034 method Methods 0.000 title claims abstract description 30
- 235000008100 Ginkgo biloba Nutrition 0.000 title claims abstract description 25
- 235000011201 Ginkgo Nutrition 0.000 title claims description 13
- 241000218628 Ginkgo Species 0.000 title description 12
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 229920005989 resin Polymers 0.000 claims description 26
- 239000011347 resin Substances 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 15
- 230000002378 acidificating effect Effects 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 150000003440 styrenes Chemical class 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 2
- 230000017531 blood circulation Effects 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 description 17
- 239000000203 mixture Substances 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 229920001429 chelating resin Polymers 0.000 description 5
- IWEIJEPIYMAGTH-UHFFFAOYSA-N Bilobetin Chemical compound COC1=CC=C(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)C=C1C1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 IWEIJEPIYMAGTH-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- YCXRBCHEOFVYEN-UHFFFAOYSA-N sciadopitysin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C(C=3C(=CC=C(C=3)C=3OC4=CC(OC)=CC(O)=C4C(=O)C=3)OC)=C2O1 YCXRBCHEOFVYEN-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
- SQGLUEWZRKIEGS-UHFFFAOYSA-N Ginkgetin Natural products C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 SQGLUEWZRKIEGS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 229930045534 Me ester-Cyclohexaneundecanoic acid Natural products 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- HITDPRAEYNISJU-UHFFFAOYSA-N amenthoflavone Natural products Oc1ccc(cc1)C2=COc3c(C2=O)c(O)cc(O)c3c4cc(ccc4O)C5=COc6cc(O)cc(O)c6C5=O HITDPRAEYNISJU-UHFFFAOYSA-N 0.000 description 2
- YUSWMAULDXZHPY-UHFFFAOYSA-N amentoflavone Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 YUSWMAULDXZHPY-UHFFFAOYSA-N 0.000 description 2
- HVSKSWBOHPRSBD-UHFFFAOYSA-N amentoflavone Natural products Oc1ccc(cc1)C2=CC(=O)c3c(O)cc(O)c(c3O2)c4cc(ccc4O)C5=COc6cc(O)cc(O)c6C5=O HVSKSWBOHPRSBD-UHFFFAOYSA-N 0.000 description 2
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- AIFCFBUSLAEIBR-UHFFFAOYSA-N ginkgetin Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C(C=1)=CC=C(OC)C=1C1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 AIFCFBUSLAEIBR-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- HUOOMAOYXQFIDQ-UHFFFAOYSA-N isoginkgetin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)OC)=C2O1 HUOOMAOYXQFIDQ-UHFFFAOYSA-N 0.000 description 2
- CGPVRBMMGYBFAC-UHFFFAOYSA-N isoginkgetin Natural products COc1ccc(cc1)C2=COc3c(C2=O)c(O)cc(O)c3c4cc(ccc4OC)C5=CC(=O)c6c(O)cc(O)cc6O5 CGPVRBMMGYBFAC-UHFFFAOYSA-N 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- NQJGJBLOXXIGHL-UHFFFAOYSA-N podocarpusflavone A Natural products COc1ccc(cc1)C2=CC(=O)c3c(O)cc(O)c(c3O2)c4cc(ccc4O)C5=COc6cc(O)cc(O)c6C5=O NQJGJBLOXXIGHL-UHFFFAOYSA-N 0.000 description 2
- VXQYICLHHMETFH-UHFFFAOYSA-N tetra-O-methylamentoflavone Natural products C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C(C=3C(=CC=C(C=3)C=3OC4=CC(OC)=CC(O)=C4C(=O)C=3)OC)=C2O1 VXQYICLHHMETFH-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- UFJORDZSBNSRQT-UHFFFAOYSA-N 3-(4-oxo-2-phenylchromen-3-yl)-2-phenylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(C=2C(C3=CC=CC=C3OC=2C=2C=CC=CC=2)=O)=C1C1=CC=CC=C1 UFJORDZSBNSRQT-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930184727 ginkgolide Natural products 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 231100000110 immunotoxic Toxicity 0.000 description 1
- 230000002625 immunotoxic effect Effects 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- -1 terpene lactones Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a method for preparing an extract from Ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones compared to the original extract, characterized by the following steps of the method:
- steps (b) and (c) may also be carried out in reverse order.
- the present invention further relates to extracts from Ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones compared to the original extract, the extracts from Ginkgo biloba being obtainable by the method according to the present invention, as well as to their use.
- Ginkgo biloba Since decades, extracts from the leaves of Ginkgo biloba are used as a medicament. They are currently used for the treatment of different types of dementia and symptoms thereof as well as cerebral and peripheral blood circulation disorders. Ingredients, the efficacy is associated with, are terpene lactones (ginkgolides A, B, and C und bilobalide) as well as glycosides of flavones (quercetin, kaempferol and isorhamnetin). However, the leaves of Ginkgo biloba also contain components, which do not contribute to the desired efficacy, but which may be responsible for risks and side effects. In addition to unpolar plant ingredients, such as ginkgolic acids, those components are 4'-O-methyl pyridoxine and biflavones.
- a Ginkgo extract which is efficacious and at the same time as safe as possible and as low in side effects as possible, these compounds should thus not be present to the largest possible extent.
- 4'-O-methyl pyridoxine may cause symptoms of poisoning such as convulsive seizures and unconsciousness.
- this compound is also referred to as ginkgotoxin.
- the biflavones contained in ginkgo exhibit an immunotoxic potential and may elicit contact allergies.
- These biflavones contained in ginkgo are predominantly the compounds amentoflavone, bilobetin, ginkgetin, isoginkgetin and sciadopitysin.
- EP 1 037 646 B1 the depletion of the biflavones and 4'-O-methyl pyridoxine is carried out at a stage of the method (step f)), wherein relatively high contents of lead salts and ammonium salts are present such that an increased amount of ion exchanger has to be employed.
- the depletion is merely described with one single ion exchanger (Merck I) in the case of 4'-O-methyl pyridoxine and with one single adsorbent (active carbon) in the case of biflavones.
- active carbon has the drawback that it typically does not bind in a very selective manner and cannot be regenerated.
- This object could be solved by separating the biflavones by adsorber resins and/or separating 4"-O-methyl pyridoxine via acidic ion exchangers.
- steps (b) and (c) may also be carried out in reverse order.
- Particularly suitable solvents in steps (a), (b) and (c) are independently aqueous ketones having 3 to 6 carbon atoms (such as acetone, 2-butanon) and alkanols having 1 to 3 carbon atoms (methanol, ethanol, n-propanol and isopropanol), preferably aqueous acetone and ethanol, a concentration of 30 to 60% by weight being preferred.
- Preferred adsorber resins in step (b) are resins on the basis of optionally substituted styrenes/divinylbenzenes such as Diaion HP-20, HP-21 or Sepabeads SP-207 and SP-850.
- Particularly preferred adsorber resins are copolymers on the basis of styrene and divinylbenzene and copolymers on the basis of brominated styrene and divinylbenzene.
- Preferred ion exchangers in step (c) are strongly acidic ion exchangers such as Merck I or Amberlite IR-120.
- the original extract used to determine the original value is obtained from the original solution (Ginkgo extract solution according to step (a)) by drying to the dry extract.
- step (b) of the method according to the present invention the amount of the resin used as well as the polarity or the composition of the solvent used have to be adjusted such that the desired components of the extract are eluted from the resin to the largest possible extent first, whereas the biflavones remain on the resin.
- a higher content of water in the solvent leads to a better depletion of the biflavones, i.e., the biflavones remain on the resin.
- the water content of the solvent is within the above-mentioned range of 30 to 70 % by weight.
- extracts the composition of which differs from the underlying single-fold extract due to one or more additional method steps to a greater or lesser extent (so- called special extracts).
- the latter extracts can be prepared, for example, by a liquid-liquid distribution according to EP 360556 B1 or by some steps according to EP 431535 B1 such as steps (a) to (c) or by the entire method according to EP 431535 B1 or according to US 6117431.
- the Ginkgo extract solutions according to step (a) can either be obtained directly from the preparation process of the extract or by dissolving a dry extract or another extract.
- a further subject of the present invention are extracts, in particular dry extracts which are obtainable by the method of the present invention and which are characterized by a reduced content of 4'-O-methyl pyridoxine and/or biflavones compared to the employed original extracts.
- the contents of 4'-O-methyl pyridoxine are 20 ppm at the most in the case of extracts according to the present invention, preferably 10 ppm at the most, and in particular 5 ppm at the most.
- the contents of biflavones are 25% of the original value of the original extract at the most, preferably 11% at the most, and in particular 6% at the most.
- dry extracts generally have a dry residue of at least 95% by weight.
- the extracts according to the present invention can be administered in the form of powders, granules, tablets, dragees (coated tablets) or capsules, preferably orally.
- the extract is mixed with suitable pharmaceutically acceptable adjuvants, such as lactose, cellulose, silicon dioxide, croscarmellose and magnesium stearate and pressed into tablets which are optionally provided with a suitable coating made of, for example, hydroxymethylcellulose, polyethyleneglycol, pigments (such as titanium dioxide, iron oxide) and talcum.
- suitable pharmaceutically acceptable adjuvants such as lactose, cellulose, silicon dioxide, croscarmellose and magnesium stearate
- a suitable coating made of, for example, hydroxymethylcellulose, polyethyleneglycol, pigments (such as titanium dioxide, iron oxide) and talcum.
- the extract according to the present invention can also be filled into capsules, optionally under the addition of adjuvants such as stabilizers, fillers and the like.
- the dosis is such
- subject of the present invention are medicaments, food products or other preparations which contain these extracts optionally in combination with other substances such as active ingredients and/or adjuvants.
- food product as used herein particularly refers to dietetic food products, dietary supplement products as well as medical food and dietary supplements.
- Example 1 according to the invention (removal of biflavones)
- Example 3 according to the invention (removal of biflavones and 4'-O-methyl pyridoxine)
- Example 4 (removal of biflavones)
- Example 5 (removal of 4'-O-methyl pyridoxine)
- Example 6 according to the present invention (removal of biflavones and 4'-O- methyl pyridoxine)
- the biflavone contents and the 4'-O-methyl pyridoxine contents of the resulting extracts can be taken from the following table. It is to be seen that the sum of the biflavones in Examples 1 , 3, 4 and 6 according to the present invention is significantly lower than in the corresponding Comparative Examples 1 and 2, respectively. Analogously, the contents of 4'-O-methyl pyridoxine are significantly reduced in Examples 2, 3, 5 and 6 according to the present invention compared to the corresponding Comparative Examples 1 and 2, respectively.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a method for preparing an extract from Ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones compared to the original extract. The invention further relates to extracts from Ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones compared to the original extract, which is obtainable by the method according to the present invention, as well as to their use.
Description
Method for preparing a Ginkgo extract having a reduced content of 4'-O-methyl pyridoxine and/or biflavones
The present invention relates to a method for preparing an extract from Ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones compared to the original extract, characterized by the following steps of the method:
(a) preparing a Ginkgo extract solution in a suitable solvent and
(b) applying the solution to an adsorber resin and eluting the purified extract from the adsorber resin using a suitable solvent, wherein the biflavones to be removed remain on the adsorber resin, and/or
(c) applying the solution to an acidic ion exchanger and eluting the purified extract from the ion exchanger using a suitable solvent, wherein the 4'-O-methyl pyridoxine to be removed remains on the ion exchanger, and optionally,
(d) concentrating and drying the extract solution to obtain a dry extract, wherein steps (b) and (c) may also be carried out in reverse order.
The present invention further relates to extracts from Ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones compared to the original extract, the extracts from Ginkgo biloba being obtainable by the method according to the present invention, as well as to their use.
Since decades, extracts from the leaves of Ginkgo biloba are used as a medicament. They are currently used for the treatment of different types of dementia and symptoms thereof as well as cerebral and peripheral blood circulation disorders. Ingredients, the efficacy is associated with, are terpene lactones (ginkgolides A, B, and C und bilobalide) as well as glycosides of flavones (quercetin, kaempferol and isorhamnetin). However, the leaves of Ginkgo biloba also contain components, which do not contribute to the desired efficacy, but which may be responsible for risks and side effects. In addition to unpolar plant ingredients, such as ginkgolic acids, those components are 4'-O-methyl pyridoxine and biflavones. In a Ginkgo extract, which is efficacious and at the same time as safe as possible and as low in side effects as possible, these compounds should thus not be present to the largest possible extent.
4'-O-methyl pyridoxine may cause symptoms of poisoning such as convulsive seizures and unconsciousness. Thus, this compound is also referred to as ginkgotoxin. The biflavones contained in ginkgo exhibit an immunotoxic potential and may elicit contact allergies. These biflavones contained in ginkgo are predominantly the compounds amentoflavone, bilobetin, ginkgetin, isoginkgetin and sciadopitysin.
4'-O-Methyl pyridoxine:
Biflavones:
Amentoflavone: R1 = R2 = R3 = H
Bilobetin: R1 = R3 = H, R2 = OCH3
Ginkgetin: R3 = H, R1 = R2 = OCH3
Isoginkgetin: R1 = H, R2 = R3 = OCH3
Sciadopitysin: R1 = R2 = R3 = OCH3
Methods for depleting 4'-O-methyl pyridoxine and biflavones as well as the extracts obtained are already described in EP 1 037 646 B1. Therein, 4'-O-methyl pyridoxine is retained using an acidic cation exchanger and the biflavones are adsorbed on activated carbon. Preferably these depletion steps are carried out after step f) of the
method according to EP 1 037 646 B1 (page 3), i.e., after "treating the solution with a lead compound or an insoluble polyamide".
In EP 1 037 646 B1 the depletion of the biflavones and 4'-O-methyl pyridoxine is carried out at a stage of the method (step f)), wherein relatively high contents of lead salts and ammonium salts are present such that an increased amount of ion exchanger has to be employed.
However, this method is limited to a complex sequence of several work-up steps.
Furthermore, the depletions of biflavones and 4'-O-methyl pyridoxine are described and claimed in combination only. However, depending on the limits to be possibly established in the future and in view of the requirement of as low a modification of the extract composition as possible, it may be desirable to remove the biflavones or 4'-O- methyl pyridoxine only.
Moreover, the depletion is merely described with one single ion exchanger (Merck I) in the case of 4'-O-methyl pyridoxine and with one single adsorbent (active carbon) in the case of biflavones. For this purpose, active carbon has the drawback that it typically does not bind in a very selective manner and cannot be regenerated.
Thus, it is the object underlying the present invention to provide a method for preparing Ginkgo extracts, wherein 4'-O-methyl pyridoxine and/or biflavones can be depleted to the largest extent possible compared to the original extract and which can additionally be carried out in a simple and cost-efficient manner. A further subject of the present invention are Ginkgo extracts, which are obtainable according to this method.
This object could be solved by separating the biflavones by adsorber resins and/or separating 4"-O-methyl pyridoxine via acidic ion exchangers.
In the method according to the present invention, the following method steps are performed:
- A -
(a) preparing a Ginkgo extract solution in a suitable solvent, as well as
(b) applying the solution to an adsorber resin and eluting the purified extract from the adsorber resin using a suitable solvent, wherein the biflavones to be removed remain on the adsorber resin and may be eluted from the resin using organic solvents, such as acetone, so that the resin can be employed again, and/or
(c) applying the solution to an acidic ion exchanger and eluting the purified extract from the ion exchanger using a suitable solvent, wherein the 4'-O-methyl pyridoxine to be removed remains on the ion exchanger and may be washed from the ion exchanger using an acid such as aqueous hydrochloric acid, so that the ion exchanger can be employed again, and optionally
(d) concentrating and drying the extract solution to obtain a dry extract, wherein steps (b) and (c) may also be carried out in reverse order.
Particularly suitable solvents in steps (a), (b) and (c) are independently aqueous ketones having 3 to 6 carbon atoms (such as acetone, 2-butanon) and alkanols having 1 to 3 carbon atoms (methanol, ethanol, n-propanol and isopropanol), preferably aqueous acetone and ethanol, a concentration of 30 to 60% by weight being preferred. Preferred adsorber resins in step (b) are resins on the basis of optionally substituted styrenes/divinylbenzenes such as Diaion HP-20, HP-21 or Sepabeads SP-207 and SP-850. Particularly preferred adsorber resins are copolymers on the basis of styrene and divinylbenzene and copolymers on the basis of brominated styrene and divinylbenzene. Preferred ion exchangers in step (c) are strongly acidic ion exchangers such as Merck I or Amberlite IR-120.
The original extract used to determine the original value is obtained from the original solution (Ginkgo extract solution according to step (a)) by drying to the dry extract.
In step (b) of the method according to the present invention, the amount of the resin used as well as the polarity or the composition of the solvent used have to be adjusted such that the desired components of the extract are eluted from the resin to
the largest possible extent first, whereas the biflavones remain on the resin. Thereby, a higher content of water in the solvent leads to a better depletion of the biflavones, i.e., the biflavones remain on the resin. Depending on the solubility of the extract, the water content of the solvent is within the above-mentioned range of 30 to 70 % by weight.
As original extracts (in the form of Ginkgo extract solutions according to step (a) or obtained therefrom) which are to be set free from 4'-O-methyl pyridoxine and/or biflavones by means of the adsorber resin, the following can be considered: • single-fold extracts prepared according to methods known per se, for example, according to the European Pharmacopoeia, by extracting dried leaves of Ginkgo biloba using organic solvents or mixtures thereof with water, for example, using ethanol/water mixtures or acetone/water mixtures or
• extracts, the composition of which differs from the underlying single-fold extract due to one or more additional method steps to a greater or lesser extent (so- called special extracts).
The latter extracts can be prepared, for example, by a liquid-liquid distribution according to EP 360556 B1 or by some steps according to EP 431535 B1 such as steps (a) to (c) or by the entire method according to EP 431535 B1 or according to US 6117431.
The Ginkgo extract solutions according to step (a) can either be obtained directly from the preparation process of the extract or by dissolving a dry extract or another extract.
A further subject of the present invention are extracts, in particular dry extracts which are obtainable by the method of the present invention and which are characterized by a reduced content of 4'-O-methyl pyridoxine and/or biflavones compared to the employed original extracts. The contents of 4'-O-methyl pyridoxine are 20 ppm at the most in the case of extracts according to the present invention, preferably 10 ppm at the most, and in particular 5 ppm at the most. The contents of biflavones are 25% of
the original value of the original extract at the most, preferably 11% at the most, and in particular 6% at the most.
According to the European Pharmacopoeia dry extracts generally have a dry residue of at least 95% by weight.
The extracts according to the present invention can be administered in the form of powders, granules, tablets, dragees (coated tablets) or capsules, preferably orally. In order to prepare tablets, the extract is mixed with suitable pharmaceutically acceptable adjuvants, such as lactose, cellulose, silicon dioxide, croscarmellose and magnesium stearate and pressed into tablets which are optionally provided with a suitable coating made of, for example, hydroxymethylcellulose, polyethyleneglycol, pigments (such as titanium dioxide, iron oxide) and talcum. The extract according to the present invention can also be filled into capsules, optionally under the addition of adjuvants such as stabilizers, fillers and the like. The dosis is such that 1 of 2000 mg, preferably 50-1000 mg, and particularly preferred 100-500 mg of the extract are administered per day.
Moreover, subject of the present invention are medicaments, food products or other preparations which contain these extracts optionally in combination with other substances such as active ingredients and/or adjuvants. The term "food product" as used herein particularly refers to dietetic food products, dietary supplement products as well as medical food and dietary supplements.
Examples
Original solution for Comparative Example 1 and Examples 1 to 3 according to the present invention
200 g dried and ground leaves of Ginkgo biloba were extracted twice using each time 7 times their weight (w/w) made up of ethanol/water 60/40 (w/w) at a temperature of about 500C and filtered.
Comparative Example 1 (preparation of a single-fold extract as the original extract)
25% of the original solution obtained above were concentrated under reduced pressure and freeze-dried: 14.0 g (28.0% based on the dried leaves).
Example 1 according to the invention (removal of biflavones)
25% of the original solution obtained above were applied to a column with 100 ml Sepabeads SP-850 adsorber resin and eluted with 300 ml 40% by weight ethanol. The eluate was concentrated under reduced pressure and freeze-dried: 11.5 g (23.0% based on the dried leaves).
Example 2 according to the invention (removal of 4'-O-methyl pyridoxine)
25% of the original solution obtained above were applied to a column with 20 ml strongly acidic ion exchanger Amberlite IR-120 and eluted with 60 ml 60% by weight ethanol. The eluate was concentrated under reduced pressure and freeze-dried: 13.0 g (26.0% based on the dried leaves).
Example 3 according to the invention (removal of biflavones and 4'-O-methyl pyridoxine)
25% of the original solution obtained above were applied to a first column with 100 ml Sepabeads SP-850 adsorber resin and eluted with 300 ml 40% by weight ethanol.
The eluate was applied to a second column with 20 ml strongly acidic ion exchanger Amberlite IR-120 and eluted with 100 ml 40% by weight ethanol. The resulting solution was concentrated under reduced pressure and freeze-dried: 10.1 g (20.2% based on the dried leaves).
Original solution for Comparative Example 2 and Examples 4 to 6 according to the present invention
20Og dried and ground leaves of Ginkgo biloba were extracted twice using each time seven times their weight (w/w) made of ethanol/water 60/40 (w/w) at a temperature of about 500C and filtered. The extract solution was largely concentrated (145 g), diluted with water to about 400 g and stored for about 19 h at 100C. The precipitate formed was removed by filtration.
Comparative Example 2 (preparation of a special extract as the original extract)
25% of the original solution obtained above were concentrated under reduced pressure and freeze-dried: 9.4 g (18.8% based on the dried leaves).
Example 4 according to the present invention (removal of biflavones)
25% of the original solution obtained above were applied to a column with 50 ml Sepabeads SP-207 adsorber resin and eluted with 150 ml 40% by weight ethanol. The eluate was concentrated under reduced pressure and freeze-dried: 9.4 g (18.8% based on the dried leaves).
Example 5 according to the present invention (removal of 4'-O-methyl pyridoxine)
25% of the original solution obtained above were applied to a column with 20 ml strongly acidic ion exchanger Amberlite IR-120 and eluted with 100 ml 40 % by weight ethanol. The eluate was concentrated under reduced pressure and freeze- dried: 8.7 g (17.4% based on the dried leaves).
Example 6 according to the present invention (removal of biflavones and 4'-O- methyl pyridoxine)
25% of the original solution obtained above were applied to a first column with 50 ml Sepabeads SP-207 adsorber resin and eluted with 150 ml 40% by weight ethanol. The eluate was applied to a second column with 20 ml strongly acidic ion exchanger Amberlite IR-120 and eluted with 100 ml 40% by weight ethanol. The resulting solution was concentrated under reduced pressure and freeze-dried: 8.3 g (16.6% based on the dried leaves).
The biflavone contents and the 4'-O-methyl pyridoxine contents of the resulting extracts can be taken from the following table. It is to be seen that the sum of the biflavones in Examples 1 , 3, 4 and 6 according to the present invention is significantly lower than in the corresponding Comparative Examples 1 and 2, respectively. Analogously, the contents of 4'-O-methyl pyridoxine are significantly reduced in Examples 2, 3, 5 and 6 according to the present invention compared to the corresponding Comparative Examples 1 and 2, respectively.
Table 1 : Composition of the extracts according to the above examples
Claims
1. Method for preparing an extract from Ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones compared to the original extract, characterized by the following method steps:
(a) preparing a Ginkgo extract solution in a solvent, and
(b) applying the solution to an adsorber resin and eluting the purified extract from the adsorber resin using a solvent, wherein the biflavones to be removed remain on the adsorber resin, and/or
(c) applying the solution to an acidic ion exchanger and eluting the purified extract from the ion exchanger using a solvent, wherein the 4'-O-methyl pyridoxine to be removed remains on the ion exchanger, and optionally
(d) concentrating and drying the extract solution to the dry extract, wherein steps (b) and (c) can also be carried out in reverse order.
2. Method according to claim 1 , wherein the solvent in steps (a), (b) and (c) is independently selected from an aqueous alkanol having 1 to 3 carbon atoms and an aqueous ketone having 3 to 6 carbon atoms.
3. Method according to claim 2, wherein the alkanol is methanol, ethanol, n- propanol or isopropanol and the ketone is acetone.
4. Method according to claim 2 or 3, wherein the water content is in a range from 30 to 70% by weight.
5. Method according to any one of claims 2 to 4, wherein the water content of the solvent in steps (a), (b) and (c) is equal or different.
6. Method according to any one of claims 1 to 5, wherein the adsorber resin is a copolymer on the basis of styrene and divinylbenzene.
7. Method according to any one of claims 1 to 5, wherein the adsorber resin is a copolymer on the basis of brominated styrene and divinylbenzene.
8. Method according to any one of claims 1 to 5, wherein the ion exchanger is a strongly acidic ion exchanger.
9. Extract from Ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones compared to the original extract, which is obtainable according to the method according to any one of claims 1 to 8.
10. Extract according to claim 9, wherein the content of 4'-O-methyl pyridoxine is 20 ppm at the most.
11. Extract according to claim 9, wherein the content of 4'-O-methyl pyridoxine is 10 ppm at the most.
12. Extract according to claim 9, wherein the content of 4'-O-methyl pyridoxine is 5 ppm at the most.
13. Extract according to any one of claims 9 to 12, wherein the content of biflavones is 25% of the original value of the original extract at the most.
14. Extract according to any one of claims 9 to 12, wherein the content of biflavones is 11 % of the original value of the original extract at the most.
15. Extract according to any one of claims 9 to 12, wherein the content of biflavones is 6% of the original value of the original extract at the most.
16. Use of the extract according to any one of claims 9 to 15 for the preparation of a medicament, food product or other preparation for the treatment of dementia and symptoms thereof and/or cerebral and peripheral blood circulation disorders.
17. Medicament, food product or other preparation characterized by a content of a Gingko extract according to any one of claims 9 to 15.
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2006243380A AU2006243380B2 (en) | 2005-05-03 | 2006-04-28 | Method for preparing a Ginkgo extract having a reduced content of 4'-O-methyl pyridoxine and/or biflavones |
| CA002606841A CA2606841A1 (en) | 2005-05-03 | 2006-04-28 | Method for preparing a ginkgo extract having a reduced content of 4'-o-methyl pyridoxine and/or biflavones |
| CN2006800134620A CN101175506B (en) | 2005-05-03 | 2006-04-28 | Method for preparing a ginkgo extract having a reduced content of 4'-o-methyl pyridoxine and/or biflavones |
| JP2008509354A JP4303778B2 (en) | 2005-05-03 | 2006-04-28 | Method for preparing ginkgo biloba extract with reduced 4'-O-methylpyridoxine and / or biflavone content |
| EP06761906A EP1868568B1 (en) | 2005-05-03 | 2006-04-28 | Method for preparing a ginkgo extract having a reduced content of 4'-o-methyl pyridoxine and/or biflavones |
| DE602006002975T DE602006002975D1 (en) | 2005-05-03 | 2006-04-28 | METHOD FOR PRODUCING A GINKGO EXTRACT WITH A REDUCED CONTENT OF 4'-O-METHYLPYRIDOXIN AND / OR BIFLAVONES |
| MX2007013399A MX2007013399A (en) | 2005-05-03 | 2006-04-28 | Method for preparing a ginkgo extract having a reduced content of 4'-o-methyl pyridoxine and/or biflavones. |
| BRPI0609298-5A BRPI0609298A2 (en) | 2005-05-03 | 2006-04-28 | Method for the preparation of a ginkgo biloba extract having a reduced content of 4'-o-methyl pyridoxine and / or biflavones, ginkgo biloba extract having a reduced content of 4'-o-methyl pyridoxine and / or biflavones extract |
| NZ563817A NZ563817A (en) | 2005-05-03 | 2006-04-28 | Method for preparing a ginkgo extract having a reduced content of 4'-O-methyl pyridoxine and biflavones |
| UAA200711513A UA84518C2 (en) | 2005-05-03 | 2006-04-28 | Method for preparing extract from ginkgo biloba having reduced content of 4'-o-methyl pyridoxine |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005020642 | 2005-05-03 | ||
| DE102005020642.5 | 2005-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006117171A1 true WO2006117171A1 (en) | 2006-11-09 |
Family
ID=36694157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2006/004039 WO2006117171A1 (en) | 2005-05-03 | 2006-04-28 | Method for preparing a ginkgo extract having a reduced content of 4'-o-methyl pyridoxine and/or biflavones |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20060251745A1 (en) |
| EP (1) | EP1868568B1 (en) |
| JP (1) | JP4303778B2 (en) |
| KR (1) | KR100925682B1 (en) |
| CN (1) | CN101175506B (en) |
| AT (1) | ATE409488T1 (en) |
| AU (1) | AU2006243380B2 (en) |
| BR (1) | BRPI0609298A2 (en) |
| CA (1) | CA2606841A1 (en) |
| DE (1) | DE602006002975D1 (en) |
| MX (1) | MX2007013399A (en) |
| NZ (1) | NZ563817A (en) |
| RU (1) | RU2356563C1 (en) |
| UA (1) | UA84518C2 (en) |
| WO (1) | WO2006117171A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2072054A1 (en) * | 2007-12-21 | 2009-06-24 | Dr. Willmar Schwabe GmbH & Co. KG | Use of a ginkgo biloba leaf extract |
| US10028986B2 (en) | 2014-02-10 | 2018-07-24 | Dr. Willmar Schwabe Gmbh & Co., Kg | Method for producing ginkgo extracts |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102614229B (en) * | 2012-04-25 | 2015-04-08 | 江苏神龙药业有限公司 | Method for removing ginkgolic acid from ginkgo biloba extract |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0360556A1 (en) * | 1988-09-20 | 1990-03-28 | INDENA S.p.A. | New extracts of ginkgo biloba and their methods of preparation |
| DE3940091A1 (en) * | 1989-12-04 | 1991-06-06 | Schwabe Willmar Gmbh & Co | EXTRACT OF BLACKERS OF GINKGO BILOBA, METHOD FOR THE PRODUCTION THEREOF AND THE EXTRACT CONTAINING MEDICAMENT |
| WO1999032129A1 (en) * | 1997-12-19 | 1999-07-01 | Dr. Willmar Schwabe Gmbh & Co. | Ginkgo biloba leaf extracts with a reduced 4'-o-methylpyridoxine and biflavone content |
| CN1557455A (en) * | 2004-02-10 | 2004-12-29 | 张正生 | Powder injection of ginko and dipyridamole and its preparing method |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6117431A (en) * | 1999-12-03 | 2000-09-12 | Pharmline Inc. | Method for obtaining an extract from ginkgo biloba leaves |
| CN100362011C (en) * | 2003-01-08 | 2008-01-16 | 浙江康恩贝制药股份有限公司 | Preparation method of ginkgo leaf extract |
| CN1318440C (en) * | 2003-01-08 | 2007-05-30 | 浙江康恩贝制药股份有限公司 | Preparation method of low-acid ginkgo leaf extract |
-
2006
- 2006-04-28 CN CN2006800134620A patent/CN101175506B/en active Active
- 2006-04-28 JP JP2008509354A patent/JP4303778B2/en not_active Expired - Fee Related
- 2006-04-28 UA UAA200711513A patent/UA84518C2/en unknown
- 2006-04-28 CA CA002606841A patent/CA2606841A1/en not_active Abandoned
- 2006-04-28 AT AT06761906T patent/ATE409488T1/en not_active IP Right Cessation
- 2006-04-28 WO PCT/EP2006/004039 patent/WO2006117171A1/en active IP Right Grant
- 2006-04-28 EP EP06761906A patent/EP1868568B1/en not_active Not-in-force
- 2006-04-28 NZ NZ563817A patent/NZ563817A/en not_active IP Right Cessation
- 2006-04-28 MX MX2007013399A patent/MX2007013399A/en active IP Right Grant
- 2006-04-28 AU AU2006243380A patent/AU2006243380B2/en not_active Ceased
- 2006-04-28 BR BRPI0609298-5A patent/BRPI0609298A2/en not_active Application Discontinuation
- 2006-04-28 KR KR1020077023532A patent/KR100925682B1/en not_active IP Right Cessation
- 2006-04-28 DE DE602006002975T patent/DE602006002975D1/en active Active
- 2006-04-28 RU RU2007144546/15A patent/RU2356563C1/en active
- 2006-05-02 US US11/416,878 patent/US20060251745A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0360556A1 (en) * | 1988-09-20 | 1990-03-28 | INDENA S.p.A. | New extracts of ginkgo biloba and their methods of preparation |
| DE3940091A1 (en) * | 1989-12-04 | 1991-06-06 | Schwabe Willmar Gmbh & Co | EXTRACT OF BLACKERS OF GINKGO BILOBA, METHOD FOR THE PRODUCTION THEREOF AND THE EXTRACT CONTAINING MEDICAMENT |
| WO1999032129A1 (en) * | 1997-12-19 | 1999-07-01 | Dr. Willmar Schwabe Gmbh & Co. | Ginkgo biloba leaf extracts with a reduced 4'-o-methylpyridoxine and biflavone content |
| CN1557455A (en) * | 2004-02-10 | 2004-12-29 | 张正生 | Powder injection of ginko and dipyridamole and its preparing method |
Non-Patent Citations (2)
| Title |
|---|
| ARENZ ANSGAR ET AL: "Occurrence of neurotoxic 4'-O-methylpyridoxine in Ginkgo biloba leaves, Ginkgo medications and Japanese Ginkgo food", 1996, PLANTA MEDICA, VOL. 62, NR. 6, PAGE(S) 548-551, ISSN: 0032-0943, XP009070428 * |
| DATABASE WPI Section Ch Week 200525, Derwent World Patents Index; Class B04, AN 2005-234134, XP002392815 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2072054A1 (en) * | 2007-12-21 | 2009-06-24 | Dr. Willmar Schwabe GmbH & Co. KG | Use of a ginkgo biloba leaf extract |
| WO2009083162A1 (en) * | 2007-12-21 | 2009-07-09 | Dr. Willmar Schwabe Gmbh & Co. Kg | Use of an extract made of leaves of ginkgo biloba |
| JP2011506512A (en) * | 2007-12-21 | 2011-03-03 | ドクター．ヴィルマー シュワーベ ゲーエムベーハー ウント ツェーオー．カーゲー | Use of extracts made from ginkgo leaves |
| US10028986B2 (en) | 2014-02-10 | 2018-07-24 | Dr. Willmar Schwabe Gmbh & Co., Kg | Method for producing ginkgo extracts |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0609298A2 (en) | 2010-03-23 |
| ATE409488T1 (en) | 2008-10-15 |
| RU2356563C1 (en) | 2009-05-27 |
| KR100925682B1 (en) | 2009-11-10 |
| AU2006243380B2 (en) | 2008-05-01 |
| NZ563817A (en) | 2010-05-28 |
| CN101175506A (en) | 2008-05-07 |
| US20060251745A1 (en) | 2006-11-09 |
| CN101175506B (en) | 2012-06-06 |
| EP1868568A1 (en) | 2007-12-26 |
| EP1868568B1 (en) | 2008-10-01 |
| JP4303778B2 (en) | 2009-07-29 |
| JP2008540355A (en) | 2008-11-20 |
| CA2606841A1 (en) | 2006-11-09 |
| KR20070112272A (en) | 2007-11-22 |
| AU2006243380A1 (en) | 2006-11-09 |
| MX2007013399A (en) | 2008-01-21 |
| UA84518C2 (en) | 2008-10-27 |
| DE602006002975D1 (en) | 2008-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8642099B2 (en) | Method for preparing ginkgo extracts having a low content of 4′-O-methyl pyridoxine and/or biflavones | |
| US20070014880A1 (en) | Method for preparing ginkgo extracts having a reduced content of nonpolar plant ingredients and nonpolar impurities due to enviromental influences | |
| WO2004080995A1 (en) | Process for producing proanthocyanin-rich material | |
| EP1868568B1 (en) | Method for preparing a ginkgo extract having a reduced content of 4'-o-methyl pyridoxine and/or biflavones | |
| EP1868626B1 (en) | Improved method for preparing ginkgo extracts having a reduced content of polycyclic aromatic hydrocarbons | |
| JP2002519383A (en) | Water-soluble natural plant dry extract, especially ginkgo extract with high content of terpenoids and flavone glycosides | |
| DE102006019861A1 (en) | Preparing extract from Ginkgo biloba having reduced content of 4'-O-methyl pyridoxine and/or biflavones for treating e.g. dementia involves preparing Ginkgo extract solution; applying solution to adsorber resin or an acidic ion exchanger | |
| JPH07206692A (en) | Hypotensor and hypotensive food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2006761906 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 3889/KOLNP/2007 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020077023532 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2008509354 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006243380 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 200680013462.0 Country of ref document: CN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 07112258 Country of ref document: CO |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/013399 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2606841 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1200702328 Country of ref document: VN |
|
| WWP | Wipo information: published in national office |
Ref document number: 2006243380 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 563817 Country of ref document: NZ |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007144546 Country of ref document: RU |
|
| WWP | Wipo information: published in national office |
Ref document number: 2006761906 Country of ref document: EP |
|
| WWG | Wipo information: grant in national office |
Ref document number: 2006761906 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: PI0609298 Country of ref document: BR Kind code of ref document: A2 |